Articles that tag PBYI but are mainly about other companies.
Puma Biotech showed modest YoY revenue growth of 7.8% and improved EPS, but faces significant earnings headwinds with expected -47.6% decline in the current quarter. The stock has gained 7.1% over the past month but received a Hold rating (Zacks Rank #3), indicating neutral near-term outlook despite a strong VGM Score of A.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
